DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/r32hrq/interfering_with) has announced the addition of the "Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2013" report to their offering.
Extra value: One year of free online updates included with this product
The extracellular matrix (ECM) consists of a complex mixture of structural and functional macromolecules and serves an important role in tissue and organ morphogenesis and in the maintenance of cell and tissue structure and function.
There are today 48 companies plus partners developing 37 targeting ECM-receptor interaction drugs in 117 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 19 drugs. Interfering With The Ecm-Receptor Interaction For The Treatment Of Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 46 different targets. These targets are further categorized on in the software application by 19 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
For more information visit http://www.researchandmarkets.com/research/r32hrq/interfering_with